Discovery of a New Drug to a Digital Center of Excellence for Chronic Itch

September 17, 2020, 4:00 pm — 4:45 pm

Due to the COVID-19 outbreak, Precision Medicine Thursdays at Venture Café have moved to Zoom.

Zoom Meeting Registration: https://zoom.us/meeting/register/tJAud–srDwoE9dFT2OQY3s8b57X2DY6YJYc

The Institute of Clinical and Translational Sciences (ICTS), in collaboration with Venture Café, is hosting Precision Medicine Series on the third Thursday of every month! This month at ICTS Precision Medicine Thursday, join us to hear the Co-Founders of Nuogen Pharma Inc., Brian Kim, MD, Associate Professor of Dermatology at Washington University School of Medicine in St. Louis and Duke Leahey, MA, CEO of SootheRX.

Based on the original discovery in the Kim Lab at WashU that Janus kinase (JAK) signaling in neurons critically mediates itch, Dr. Brian Kim and Duke Leahey co-founded Nuogen Pharma to develop JAK inhibitors for itch by way of a novel route of delivery. Currently, there are no FDA-approved medications specifically for chronic itch. Beyond treatments, recognizing the highly unmet need for patients in terms of diagnosis, education, management, and access, Dr. Kim and Duke decided to start an online digital center of excellence called SootheRx. This platform aims to revolutionize and innovate the delivery of care itself while simultaneously bringing new treatments to patients with chronic itch in the most effective and efficient manner possible.

For more information, please contact Tricia Salyer, Precision Medicine Navigator at ICTS, at salyerp@wustl.edu.